Description of Medical ServiceGermline BRCA mutation testing to detect the presence of a BRCA1 or BRCA2 gene variant in a patient with, HER2-negative, high risk early breast cancer.
Description of Medical ConditionIn Australia, breast cancer is the most common cancer affecting women and early breast cancer includes Stages I-IIIa. Patients with a germline BRCA gene variant are typically younger than the overall breast cancer population. Patients with triple negative breast cancer (TNBC) are known to have a higher risk of tumours presenting with a BRCA mutation. TNBC refers to breast cancer that does not present with the three most common types of receptors known to fuel breast cancer growth (estrogen, progesterone, and the human epidermal growth factor receptor 2 gene (HER-2)). This form of cancer tends to be more aggressive than other breast cancer sub-types, with a poor prognosis, and is more likely to affect younger, pre-menopausal women.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1607 KB)
Application Form (Word 258 KB)
Consultation SurveyConsultation Survey (PDF 660 KB)
Consultation Survey (Word 27 KB)
Expedited - Bypassing PASC
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process